ZBTB7A Knockout cell line (HeLa)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZBTB7A (zinc finger and BTB domain containing 7A) encodes a zinc finger transcriptional regulator with BTB and zinc finger domains that mediate protein interactions and DNA-associated regulatory functions. The protein interacts with SMAD proteins, androgen receptors, and transcriptional coregulators and participates in regulation of RNA polymerase II-dependent gene expression. ZBTB7A contributes to processes including erythrocyte maturation and regulation of cellular signaling and metabolism.

The HeLa cell line is a globally utilized immortal human cervical cancer cell line, historically distinguished as the first aneuploid, continuously cultured human cell line established in 1951. Originally isolated from an epitheloid cervix carcinoma of a 31-year-old Black female (with a later updated diagnosis of adenocarcinoma), HeLa cells are characterized by their rapid proliferation and exceptionally stable growth profiles. Serving as a foundational model in cancer research, gene editing (e.g., CRISPR), and drug screening, this line also plays a critical role in virology due to its high susceptibility to Poliovirus type I and adenovirus type 3. Because of its robust growth advantage, HeLa has been frequently identified as a prominent cross-contaminant in numerous other cell lines, and therefore must be strictly managed and handled under laboratory containment level 2.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.